Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

Date Title and Summary Additional Formats
Toggle Summary OXiGENE to Commence a Randomized Clinical Trial in the United States to Evaluate CA4P for the Treatment of Patients with Non Small Cell Lung Cancer (NSCLC)
OXiGENE to Commence a Randomized Clinical Trial in the United States to Evaluate CA4P for the Treatment of Patients with Non Small Cell Lung Cancer (NSCLC) WALTHAM, Mass., Feb 03, 2006 (BUSINESS WIRE) -- OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) -- Combretastatin A4P (CA4P) will be Evaluated with
View HTML
Toggle Summary OXiGENE to Focus Ophthalmology Strategy Toward Non-Invasive Administration of CA4P for Age-Related Macular Degeneration (AMD); Closes Enrollment of Phase II CA4P Clinical Trial in Myopic Macular Degeneration (MMD-213)
OXiGENE to Focus Ophthalmology Strategy Toward Non-Invasive Administration of CA4P for Age-Related Macular Degeneration (AMD); Closes Enrollment of Phase II CA4P Clinical Trial in Myopic Macular Degeneration (MMD-213) WALTHAM, Mass., Sep 12, 2006 (BUSINESS WIRE) -- OXiGENE, Inc.
View HTML
Toggle Summary CORRECTION: OXiGENE Participates in 4th Annual International Conference on Antiangiogenesis
CORRECTION: OXiGENE Participates in 4th Annual International Conference on Antiangiogenesis WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 11, 2006--This replaces the announcement made at 14:00 ET on October 10, 2006 due to the following correction: first graph, second sentence of release should read: Dr.
View HTML
Toggle Summary David Chaplin, Ph.D, Chief Scientific Officer and Head of Research and Development at OXiGENE, Named Executive Vice Chairman of the Company's Board of Directors
David Chaplin, Ph.D, Chief Scientific Officer and Head of Research and Development at OXiGENE, Named Executive Vice Chairman of the Company's Board of Directors WALTHAM, Mass., Dec 01, 2005 (BUSINESS WIRE) -- OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN): -- Dr.
View HTML
Toggle Summary Distinguished Oncology Researcher, Dr. Robert Kerbel, Discusses the Therapeutic Potential of Pairing Vascular Disrupting Agents with Anti-Angiogenic Drugs in the Fight against Cancer at AACR Conference
Distinguished Oncology Researcher, Dr. Robert Kerbel, Discusses the Therapeutic Potential of Pairing Vascular Disrupting Agents with Anti-Angiogenic Drugs in the Fight against Cancer at AACR Conference WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 10, 2005--OXiGENE, Inc.
View HTML
Toggle Summary Drug Development Experts Nicole Onetto, M.D., and Eric Rowinsky, M.D. Join Symphony ViDA Board of Directors
Combined Experience Includes Integral Involvement in Development of Multiple Blockbuster Oncology Products, Including Erbitux(r), Tarceva(r) and Taxol(r)
View HTML
Toggle Summary First Patient Enrolled in OXiGENE's Phase Ib Trial of its Lead Vascular Disrupting Agent, CA4P, in Combination with an Antiangiogenic Agent, Bevacizumab (Avastin) for the Treatment of Advanced Cancer
First Patient Enrolled in OXiGENE's Phase Ib Trial of its Lead Vascular Disrupting Agent, CA4P, in Combination with an Antiangiogenic Agent, Bevacizumab (Avastin) for the Treatment of Advanced Cancer WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 8, 2006--OXiGENE, Inc.
View HTML
Toggle Summary Internationally Recognized Top Neurosurgeon Joins the Medical Advisory Board of Oncotelic
AGOURA HILLS, Calif. , July 16, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic"), a wholly owned subsidiary of Mateon Therapeutics Inc. (OTCQB:MATN) dedicated to development of innovative treatments for cancer, announced today that Dr. John H. Sampson , an internationally recognized
View HTML
Toggle Summary JCEM Publishes Data from OXiGENE-sponsored Preclinical Study of Combretastatin A4 phosphate / CA4P Triple-Drug Combinations in Anaplastic Thyroid Cancer
Triple-drug combination therapy shows promising antineoplastic activity
View HTML
Toggle Summary Mateon and Oncotelic Complete Their Merger and Create a New Immuno-Oncology Company with a Late-Stage Clinical Asset Against Cancer and a Promising Product Pipeline
-Merger creates a publicly-traded clinical stage immuno-oncology company developing treatments for advanced cancers including aggressive brain tumors, pancreatic cancer, and melanoma   -Phase 2 clinical data on lead product candidate OT-101 demonstrated robust tumor responses including complete
View HTML